A Study to Evaluate ALN-2232 in Participants With Obesity

What Was Tested

This registered phase 1, phase 2 trial tested Tirzepatide.

It had seven arms (groups): Part A: ALN-2232 (experimental), Part A: Placebo (placebo comparator), Part B: ALN-2232 (experimental), Part B: Placebo (placebo comparator) and Part C: ALN-2232 (experimental).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 156 planned participants were the target.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Has a body mass index (BMI) of ≥30 kg/m\^2 and \<40 kg/m\^2.

The full record lists 2 inclusion and 2 exclusion criteria; among the exclusions: receiving therapies for chronic weight management or antidiabetic medications.

How the Study Was Run

It was run as a randomized, parallel-group and triple-blind study.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

The Tirzepatide group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Tirzepatide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2026-03-02 with completion listed for 2027-04-28.

It ran at 1 site in Canada.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Part A: Frequency of Adverse Events (AEs) (time frame: Up to 12 months). Part B: Percent Change from Baseline in Body Weight (time frame: Baseline up to Month 6). Part C: Percent Change from Baseline in Body Weight (time frame: Baseline up to Month 6).

It also tracked 9 secondary outcomes, for example Part A: Change from Baseline in Proteins in Adipose Tissue, Part A: Area Under the Plasma Concentration-time Curve (AUC) of ALN-2232 in Plasma, Part A: Maximum Observed Plasma Concentration (Cmax) of ALN-2232 in Plasma, Part A: Time to Maximum Plasma Concentration (Tmax) of ALN-2232 in Plasma, Part A: Fraction of ALN-2232 excreted in urine and Part A: Percent Change from Baseline in Body Weight.

What This Means in Plain Language

Put simply, this is a phase 1, phase 2, randomized trial of Tirzepatide in 156 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.